Evaxion A/S has made headlines with its latest report on the personalized cancer vaccine EVX-01, revealing an impressive 89% vaccine target precision. This significant milestone comes from a phase 2 trial involving patients with advanced melanoma, showcasing the potential of AI-driven immunotherapies in the fight against cancer.

The results indicate that EVX-01 induced an immune response in all patients involved in the trial, with 89% of the vaccine neoantigens generating potent specific T-cell responses. This finding is particularly noteworthy as it suggests a high level of efficacy for the vaccine, which is designed to be personalized based on each patient's unique tumor profile.

Background

Evaxion A/S is a clinical-stage TechBio company based in Hoersholm, Denmark, specializing in the development of innovative immunotherapies through its proprietary AI-Immunology™ platform. The company operates under the Standard Industrial Classification of Biological Products, (No Diagnostic Substances) (SIC 2836) and is listed on the Nasdaq under the ticker EVAX. Recent filings include multiple reports leading up to this significant announcement, with the latest 6-K form filed on October 23, 2026.

What the Filing Says

The recent filing states, "Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01." This highlights the sustained efficacy of the vaccine over three years, with no tumor progression observed in patients who received the treatment.

Impact

This development may have far-reaching implications for patients with advanced melanoma, as well as for the broader biotechnology industry. The results could influence treatment protocols and encourage further investment in AI-driven therapies. Competitors in the biological products sector may need to adjust their strategies in response to Evaxion's promising findings.

What's Next

Following this announcement, Evaxion will present the trial data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid on October 24, 2026. Additionally, a webinar is scheduled for October 29, 2026, where key opinion leaders will discuss the implications of these findings.